Evidence map›Paper›PMID 23743662›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2013

Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production.

Zhilin Qi, Fei Yin, Lina Lu, Lei Shen, Shimei Qi, Lei Lan, Lan Luo, Zhimin Yin

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Therapeutic effect of baicalein as an antiparasitic agent againstJournal of Zhejiang University. Science. B · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Baicalein Induces GMolecules (Basel, Switzerland) · 2023
    Article
  8. Therapeutic Potential of Bioactive Components fromInternational journal of molecular sciences · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Intracellular ROS Scavenging and Anti-Inflammatory Activities ofEvidence-based complementary and alternative medicine : eCAM · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Identification of Chinese Herbal Compounds with Potential as JAK3 Inhibitors.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhilin QiJiangsu Province Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing 210046, Jiangsu, People's Republic of China.
Fei Yin
Lina Lu
Lei Shen
Shimei Qi
Lei Lan
Lan Luo
Zhimin Yin
Nanjing Normal University · CNNanjing University · CNWannan Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the precise molecular mechanisms by which baicalein exerts beneficial biochemical activities in RAW264.7 macrophages treated with LPS. MATERIALS AND

methodsRAW264.7 cells were cultured in the absence or presence of baicalein together with or without LPS. iNOS and COX-2 expression were measured by western blot and RT-PCR analyses. TNF-α, IL-1β, and IL-6 were determined by using double-antibody sandwich ELISA. Phosphorylations of JAK1 and JAK2, and of STAT1 and STAT3 were detected by western blotting. Nuclear translocation of STAT1 and STAT3 was visualized by confocal microscopy. ROS production was detected by ROS assay.

resultsBaicalein significantly reduced the phosphorylation of STAT1 and STAT3 and the phosphorylation of JAK1 and JAK2, but without affecting MAPKs phosphorylation in LPS-stimulated RAW264.7 cells. Baicalein suppressed the nuclear translocation of STAT1 and STAT3 and inhibited production of iNOS upon LPS-stimulation, resulting in the inhibition of releases of NO and pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, in a dose-dependent manner. In addition, we found that baicalein reduced the LPS-induced accumulation of ROS, confirming that baicalein serves as an antioxidant.

conclusionsOur results suggested that suppressing JAK/STATs activation and interfering with ROS production might contribute to the anti-inflammatory action of baicalein in macrophages.

Indexed as

AnimalsAnti-Inflammatory AgentsCells, CulturedCyclooxygenase 2Dose-Response Relationship, DrugFlavanonesInflammationInterleukin-1betaInterleukin-6Janus Kinase 1Janus Kinase 2LipopolysaccharidesMacrophagesMiceModels, AnimalNitric Oxide Synthase Type IIAnti-Inflammatory AgentsbaicaleinCyclooxygenase 2FlavanonesInterleukin-1betaInterleukin-6Janus Kinase 1Janus Kinase 2LipopolysaccharidesNitric Oxide Synthase Type IIReactive Oxygen SpeciesStat1 protein, mouseSTAT1 Transcription FactorStat3 protein, mouseSTAT3 Transcription FactorTumor Necrosis Factor-alpha

Identifiers

PMID23743662
OpenAlexW1990421417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.